DNLI logo

DNLI
Denali Therapeutics Inc

1,909
Mkt Cap
$3.04B
Volume
1.91M
52W High
$23.77
52W Low
$10.57
PE Ratio
-6.63
DNLI Fundamentals
Price
$19.68
Prev Close
$19.20
Open
$19.56
50D MA
$20.48
Beta
1.68
Avg. Volume
1.97M
EPS (Annual)
-$2.97
P/B
3.03
Rev/Employee
$0.00
$2,024.85
Loading...
Loading...
News
all
press releases
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...
PR Newswire·1d ago
News Placeholder
More News
News Placeholder
Equities Analysts Offer Predictions for DNLI FY2027 Earnings
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to...
MarketBeat·3d ago
News Placeholder
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.
Zacks·6d ago
News Placeholder
Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock
Morgan Stanley boosted their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Thursday...
MarketBeat·6d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7% - Time to Sell?
Denali Therapeutics (NASDAQ:DNLI) Shares Down 5.7% - Here's What Happened...
MarketBeat·6d ago
News Placeholder
The Goldman Sachs Group Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock
The Goldman Sachs Group lifted their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says
Stifel Nicolaus raised their price objective on shares of Denali Therapeutics from $34.00 to $41.00 and gave the company a "buy" rating in a research report on Thursday...
MarketBeat·6d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Given New $38.00 Price Target at BTIG Research
BTIG Research lifted their price objective on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday...
MarketBeat·7d ago
News Placeholder
Robert W. Baird Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock
Robert W. Baird increased their price target on Denali Therapeutics from $29.00 to $32.00 and gave the stock an "outperform" rating in a research report on Thursday...
MarketBeat·7d ago
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock
HC Wainwright upped their target price on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday...
MarketBeat·7d ago
<
1
2
...
>

Latest DNLI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.